MRKR
Price:
$3.38
Market Cap:
$30.16M
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and...[Read more]
Industry
Biotechnology
IPO Date
2002-07-16
Stock Exchange
NASDAQ
Ticker
MRKR
According to Marker Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 3.15. This represents a change of -39.26% compared to the average of 5.19 of the last 4 quarters.
The mean historical Current Ratio of Marker Therapeutics, Inc. over the last ten years is 6.84. The current 3.15 Current Ratio has changed 4.51% with respect to the historical average. Over the past ten years (40 quarters), MRKR's Current Ratio was at its highest in in the December 2019 quarter at 22.83. The Current Ratio was at its lowest in in the June 2016 quarter at 0.16.
Average
6.84
Median
3.69
Minimum
0.18
Maximum
22.83
Discovering the peaks and valleys of Marker Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.96%
Maximum Annual Current Ratio = 22.83
Minimum Annual Increase = -83.29%
Minimum Annual Current Ratio = 0.18
Year | Current Ratio | Change |
---|---|---|
2023 | 5.57 | 160.82% |
2022 | 2.14 | -40.08% |
2021 | 3.56 | -6.53% |
2020 | 3.81 | -83.29% |
2019 | 22.83 | 3.22% |
2018 | 22.11 | 549.82% |
2017 | 3.40 | -25.39% |
2016 | 4.56 | 1.82% |
2015 | 0.24 | 31.95% |
2014 | 0.18 | 1.96% |
The current Current Ratio of Marker Therapeutics, Inc. (MRKR) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
3.76
5-year avg
7.58
10-year avg
6.84
Marker Therapeutics, Inc.’s Current Ratio is greater than Lumos Pharma, Inc. (2.66), greater than Exicure, Inc. (0.71), greater than Protagenic Therapeutics, Inc. (1.80), less than PMV Pharmaceuticals, Inc. (13.98), less than Anebulo Pharmaceuticals, Inc. (3.45), less than Miromatrix Medical Inc. (3.46), greater than ZIVO Bioscience, Inc. (0.17), less than Bionomics Limited (3.30), greater than Agenus Inc. (0.19), less than Icosavax, Inc. (18.06), less than Galera Therapeutics, Inc. (9.74), less than Edgewise Therapeutics, Inc. (26.35), less than RenovoRx, Inc. (5.66), greater than Tempest Therapeutics, Inc. (1.69), less than Ikena Oncology, Inc. (15.32), less than Catalyst Biosciences, Inc. (3.72), less than Acrivon Therapeutics, Inc. Common Stock (12.75), less than Alector, Inc. (3.29), less than Aadi Bioscience, Inc. (4.89), less than Keros Therapeutics, Inc. (19.03), less than Aerovate Therapeutics, Inc. (8.78),
Company | Current Ratio | Market cap |
---|---|---|
2.66 | $37.54M | |
0.71 | $44.77M | |
1.80 | $3.34M | |
13.98 | $76.07M | |
3.45 | $42.01M | |
3.46 | $92.95M | |
0.17 | $78.37M | |
3.30 | $789.08M | |
0.19 | $64.51M | |
18.06 | $769.04M | |
9.74 | $1.63M | |
26.35 | $2.80B | |
5.66 | $30.96M | |
1.69 | $37.39M | |
15.32 | $73.83M | |
3.72 | $19.42M | |
12.75 | $193.98M | |
3.29 | $181.18M | |
4.89 | $73.94M | |
19.03 | $676.88M | |
8.78 | $75.07M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Marker Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Marker Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Marker Therapeutics, Inc.'s Current Ratio?
How is the Current Ratio calculated for Marker Therapeutics, Inc. (MRKR)?
What is the highest Current Ratio for Marker Therapeutics, Inc. (MRKR)?
What is the 3-year average Current Ratio for Marker Therapeutics, Inc. (MRKR)?
What is the 5-year average Current Ratio for Marker Therapeutics, Inc. (MRKR)?
How does the current Current Ratio for Marker Therapeutics, Inc. (MRKR) compare to its historical average?